Original Research

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer

Chrisoulidou A, Mandanas S, Margaritidou E, Mathiopoulou L, Boudina M, Georgopoulos K, Pazaitou-Panayiotou K

OncoTargets and Therapy 2015, 8:2435-2442

Published Date: 3 September 2015